CA-NETAPP
17.5.2022 14:02:08 CEST | Business Wire | Press release
NetApp® (NASDAQ: NTAP), a global, cloud-led, data-centric software company, today announced the general availability of Spot PC, the managed cloud Desktop-as-a-Service (DaaS) solution — with security, automation, observability and optimization designed for the public cloud and for the needs of today’s remote and distributed working environments.
Available today, Spot PC provides Managed Service Providers (MSPs) and their customers with a cloud desktop solution optimized for security, privacy and infrastructure efficiency, with predictable pricing to reduce overall support burdens and allow existing staff to deliver and support many more desktops, increasing profitability.
With the rapid acceleration of hybrid work environments, organizations have been compelled to evolve their IT infrastructure to support remote work environments, building distributed teams, and enabling hybrid offices while navigating supply chain issues and cyber security threats.
But the most common solutions available to deliver remote desktops, based on traditional virtual desktop infrastructure (VDI) were never designed for the public cloud and therefore require significant effort for administration, management and troubleshooting. As a result, today’s remote desktop offerings come with significant operations burdens, can be time consuming and complex to set up, migrate to, and manage, and are expensive to deploy and operate.
“Service providers and enterprises today require the right tools and solutions that are built for the cloud for optimal efficiency of their resources,” said Anthony Lye, Executive Vice President of Public Cloud Services at NetApp. “With Spot PC, we’re equipping MSPs and enterprises to bring differentiated, profitable cloud desktop solutions to market to meet growing demand from their customers and enabling them to deliver flexible, secure and fit-for-purpose remote work experiences to a variety of users across multiple locations and regions.”
Spot PC delivers a comprehensive as-a-service solution to these challenges, enabling MSPs and enterprises to provide secure, reliable, and fully optimized cloud desktops to support a broad range of needs.
Spot PC provides MSPs and enterprises with the ability to:
- Deliver cloud desktops with speed, flexibility and agility across multiple locations and regions to support a wide range of tasks for knowledge and technical computing users
- Ensure that cloud desktop environments meet security, availability and performance requirements without overburdening IT staff
- Provide predictable cost structure using patent-pending AI and machine learning automated optimization
“We are really excited for Spot PC and the benefits and automation it will provide us and our clients,” said Derek Anderson, President at Biztek Solutions. “We see Spot PC as the go to solution for secure, cloud hosted desktops that will enable businesses to adopt remote and hybrid work environments that easily scale with their business.”
“Working with NetApp has meant that Cloud PC as a Service has become an exciting prospect for our clients to enjoy Spot PC, combined with complete support for the virtual desktop and the office suite that our clients use,” said Peter Beglan, CEO at Cloud PC Ltd & HyCloud Ltd. “We are so confident that this combined virtual desktop solution will be eagerly received in the UK that we have already made plans to start offering Cloud PC as a Service within the European marketplace.”
Spot PC is available today, direct from NetApp for enterprises and service providers with a fixed pricing structure per user per month.
Additional Resources:
About NetApp
NetApp is a global, cloud-led, data-centric software company that empowers organizations to lead with data in the age of accelerated digital transformation. The company provides systems, software and cloud services that enable them to run their applications optimally from data center to cloud, whether they are developing in the cloud, moving to the cloud, or creating their own cloudlike experiences on premises. With solutions that perform across diverse environments, NetApp helps organizations build their own data fabric and securely deliver the right data, services and applications to the right people—anytime, anywhere. Learn more at www.netapp.com or follow us on Twitter , LinkedIn , Facebook , and Instagram .
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517005461/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom